Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 2/2014

Open Access 01-04-2014 | Letter

Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’ – authors’ reply

Authors: Jérémie Sellam, Soraya Fellahi, Jean-Philippe Bastard, Jacqueline Capeau, Francis Berenbaum

Published in: Arthritis Research & Therapy | Issue 2/2014

Login to get access

Excerpt

We thank Dr Toussirot for his interest [1] in our work demonstrating that serum-level adiponectin is associated with subsequent radiographic progression in early rheumatoid arthritis (RA) [2]. We would like to respond to each comment. …
Literature
1.
Toussirot E: Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’. Arthritis Res Ther. 2014, 16: 407-PubMedCentralCrossRefPubMed
2.
Meyer M, Sellam J, Fellahi S, Kotti S, Bastard JP, Meyer O, Lioté F, Simon T, Capeau J, Berenbaum F: Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther. 2013, 15: R210-10.1186/ar4404.PubMedCentralCrossRefPubMed
3.
Frommer KW, Schäffler A, Büchler C, Steinmeyer J, Rickert M, Rehart S, Brentano F, Gay S, Müller-Ladner U, Neumann E: Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis?. Ann Rheum Dis. 2012, 71: 1724-1732. 10.1136/annrheumdis-2011-200924.CrossRefPubMed
4.
Miller M, Pham A, Cho JY, Rosenthal P, Broide DH: Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema. Am J Physiol Lung Cell Mol Physiol. 2010, 299: L834-L842. 10.1152/ajplung.00326.2009.PubMedCentralCrossRefPubMed
5.
Toussirot E, Grandclément E, Gaugler B, Michel F, Wendling D, Saas P, Dumoulin G: CBT-506: Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis, A comparative study. Front Immunol. 2013, 4: 453-PubMedCentralCrossRefPubMed
6.
Dessein PH, Woodiwiss AJ, Norton GR, Tsang L, Solomon A: Independent associations of total and high molecular weight adiponectin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2013, 15: R128-10.1186/ar4308.PubMedCentralCrossRefPubMed
Metadata
Title
Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’ – authors’ reply
Authors
Jérémie Sellam
Soraya Fellahi
Jean-Philippe Bastard
Jacqueline Capeau
Francis Berenbaum
Publication date
01-04-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4538

Other articles of this Issue 2/2014

Arthritis Research & Therapy 2/2014 Go to the issue

Research article

Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients

Research article

Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study

Research article

Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study

Editorial

Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?

Editorial

Tumor necrosis factor: is it time to change the name?

Commentary

Might axial myofascial properties and biomechanical mechanisms be relevant to ankylosing spondylitis and axial spondyloarthritis?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits